Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oncology Price Scale Tips Higher: Seattle Genetics Adcetris To Cost Over $100K

This article was originally published in The Pink Sheet Daily

Executive Summary

Amid record-topping oncology drug prices, yet another high-priced therapy will hit the market, following accelerated approval from FDA.
Advertisement

Related Content

“Emerging Sponsors” Pose Regulatory, Public Relations Challenges For Drug Review Process, FDA’s Jenkins Says
Seattle Genetics Commits To Simultaneous Confirmatory Trials For Adcetris
Seattle Genetics Commits To Simultaneous Confirmatory Trials For Adcetris
Disappointing Provenge Sales Stir Doubts About Demand
Seattle Genetics Hoping Its Adcetris Trials Can Do Double Duty

Topics

Advertisement
UsernamePublicRestriction

Register

PS072673

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel